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Abstract
Detection of hepatocellular carcinoma (HCC) through screening can improve outcomes.
However, HCC surveillance remains costly, cumbersome and suboptimal. We tested
whether and how serum Alpha-Fetoprotein (AFP) should be used in HCC surveillance.
Record linkage, dedicated pathways for management and AFP data-storage identified i)
consecutive highly characterised cases of HCC diagnosed in 2009–14 and ii) a cohort of
ongoing HCC-free patients undergoing regular HCC surveillance from 2009. These two
well-defined Scottish patient cohorts enabled us to test the utility of AFP surveillance. Of
304 cases of HCC diagnosed over 6 years, 42% (129) were identified by a dedicated HCC
surveillance programme. Of these 129, 47% (61) had a detectable lesion first identified by
screening ultrasound (US) but 38% (49) were prompted by elevated AFP. Despite pre-HCC
diagnosis AFP >20kU/L being associated with poor outcome, ‘AFP-detected’ tumours were
offered potentially curative management as frequently as ‘US-detected’ HCCs; and had
comparable survival. Linearity of serial log10-transformed AFPs in HCC cases and in the
screening ‘HCC-free’ cohort (n = 1509) provided indicators of high-risk AFP behaviour in
HCC cases. An algorithm was devised in static mode, then tested dynamically. A case/con-
trol series in hepatitis C related disease demonstrated highly significant detection
(p<1.72*10−5) of patients at high risk of developing HCC. These data support the use of
AFP in HCC surveillance. We show proof-of-principle that an automated and further refine-
able algorithmic interpretation of AFP can identify patients at higher risk of HCC. This
approach could provide a cost-effective, user-friendly and much needed addition to US
surveillance.
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Introduction
Hepatocellular carcinoma (HCC) is an enormous burden to global health. In adult men HCC
is now the fifth most frequently diagnosed cancer, and the second leading cause of cancer-
related death worldwide [1, 2]. Despite widely implemented screening programmes and
improved therapies, HCC is predicted to continue as a major problem for the foreseeable
future. Late HCC detection, particularly in symptomatic patients, leaves few effective therapeu-
tic options and is associated with extremely poor outcome [2, 3]. However, the early detection
of asymptomatic HCC through screening programmes in high risk populations has improved
outcomes in specific contexts and does permit potentially curative therapies [4–7].
Based upon the high risk of HCC in a large but definable population, combined with mini-
mally invasive screening tests and genuine curative options for early cancers, HCC represents a
suitable target for surveillance programmes. However, the optimal methodology for imple-
menting HCC surveillance remains highly debated.
Serum Alpha-Fetoprotein (AFP) is the most widely used biomarker in HCC surveillance
programmes and, until recently, was included in international guidelines for HCC surveillance
[8–10]. AFP has significant limitations as a screening test: specifically, in one third to half of
HCC cases AFP will not be significantly elevated [11–14]. Conversely, AFP can be chronically
elevated or time-varying in a subset of HCC-free patients [13, 15]. Nonetheless, AFP elevations
are associated with greater long term risk of HCC development [16].
The practical use of AFP is complex and suboptimal due to varying recommendations on
the upper limit of normal (ULN) with associated variability in sensitivity and specificity
depending on the ULN applied [11] which may vary between aetiologies of the underlying liver
disease, ethnicity and sex [13, 17–19]. The absence of better serum biomarkers and the prob-
lems of cumulative radiation exposure and cost associated with cross sectional imaging leaves
ultrasound (US) as the currently recommended sole modality of surveillance [9, 10]. Unfortu-
nately, as a screening test, US itself is suboptimal in its sensitivity and specificity for HCC
detection [13, 20]. Although AFP has been removed from updated international guidelines for
HCC surveillance, a number of recent reports propose a rationale for the ongoing use of AFP
[21–23].
Refining AFP use through alternative methodologies for AFP interpretation has been pro-
posed to improve HCC detection and possibly cost efficiency [15, 17, 23–27]. These studies
rely on operator interpretation of AFPs, often over a specified time scale, which is likely to cre-
ate difficulties in the real world where there is already a wide variation in how HCC surveil-
lance is practised even by specialist clinicians [28]. Furthermore, gaps in knowledge about
HCC surveillance in practice have been identified as a frequent factor leading to failure to
engage primary care physicians in HCC surveillance programmes [29–31]. Therefore, a poten-
tial improvement could be the development of an automated personalised interpretation of an
individual patient’s AFP screening results capable of operating adaptively over varying screen-
ing intervals.
Despite the removal of AFP from surveillance guidelines, monitoring of the HCC-risk pop-
ulation in Lothian, South East Scotland, continued to employ local guidelines of bi-annual sur-
veillance using US and AFP, aided by the graphical display of AFP levels over time in a
patient’s record from a dedicated tumour marker database. For both all newly diagnosed HCC
cases and a large cohort of patients in HCC-surveillance in 2009 (for whom all AFP results
were available) we investigated the role of AFP in the clinical pathway leading to HCC diagno-
sis and whether formal automated analysis of dynamic AFP can facilitate HCC detection and
enable curative treatment. Here, in a proof of principle study, we show that specialist
Dynamic Alpha-Fetoprotein in Hepatocellular Carcinoma Screening
PLOS ONE | DOI:10.1371/journal.pone.0156801 June 16, 2016 2 / 22
Thomas G. Bird (Tel. 01413306489, Email:
t.bird@beatson.gla.ac.uk).
Funding: TGB is supported by an Academy of
Medical Science Starter Grant for Clinical Lecturers
and a Wellcome Trust Intermediate Fellowship
(107492/z/15/z). SMB and PD were supported by
Medical Research Council (MRC) programme
MC_U105260794, RT by MRC programme
MC_U105260558. The funders had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: SMB holds shares in GSK,
but this does not alter our adherence to PLOS ONE
policies on sharing data and materials. The authors
who have taken part in this study have otherwise
declared that they do not have anything to disclose
regarding funding or conflict of interest with respect to
this manuscript.
interpretation of dynamic AFP changes over time can be modelled and a standardised auto-
matic algorithm devised to identify early a subset of patients at higher risk of HCC
development.
Methods
Patient identification and data retrieval
Lothian is a distinct region of South East Scotland providing universal healthcare for approxi-
mately 800,000 inhabitants. Coordinated care is facilitated by unified secondary healthcare rec-
ords and a unique individual patient identifier: Community Health Index (CHI). Anonymised
patient data were collected and analysed under local ethics approval granted by South East
Scotland Research Ethics service (Caldicott ref NR/1201AB15). A dedicated regional hub
(Royal Infirmary of Edinburgh) receives all regional referrals of suspected HCC for diagnosis,
and their management is guided in accordance with local guidelines at a regional multidisci-
plinary meeting. On-site regional interventional radiology, tertiary hepatobiliary surgical and
the national liver transplant services are available.
Serum AFP detection
Serum samples throughout the region are collected in a unified blood collection system and
analysed in a central laboratory using ADVIA Centaur XP Immunoassay System (Siemens) or
Architect AFP assay (Abbott Laboratories) which were validated for comparability. Results are
reported as kU/L (Conversion factor 0.83kU/L = 1ug/L).
Review of HCC cases
Records for all referrals of suspected HCC from October 2008 to February 2015 were reviewed
by a local specialist (TGB) to identify newly diagnosed HCC cases, cross-referenced with ICD-
10 codes and a local liver transplant database. Diagnosis of HCC was based upon international
guidelines for imaging and histopathological criteria [8, 9]. Referred to hereafter as the ‘HCC
case series’, data were retrieved as follows: survival status at census date, patient age at diagno-
sis, aetiology of chronic liver disease, sex, AFP dates and results, imaging modality dates and
results, pathological sample reports and dates. All interventional therapies and procedures
(liver transplant, surgical resection by partial hepatectomy, trans-arterial chemoembolization,
radiofrequency ablation, and/or Sorafenib therapy) and associated dates were recorded
together with size (mm) and number of HCC lesions at the time of diagnosis. Detailed review
of electronic case-notes established the clinical path by which HCC was detected. The date of
HCC diagnosis was defined as the date of an imaging procedure, biopsy or surgery which led to
the first diagnosis of HCC in each patient. Patients with HCC diagnosed between 1st January
2009 and 31st December 2014 were included in the analyses. Cases were excluded whose origi-
nal referral was outwith the Lothian region, or if the radiological diagnosis of HCC was in
doubt or excluded subsequently by histology. Data detailing AFP values in this cohort have
been deposited in Edinburgh DataShare: http://dx.doi.org/10.7488/ds/1395.
HCC surveillance cohort: identification
A separate cohort of patients undergoing intentional HCC surveillance with AFP was identi-
fied. Local guidelines throughout the study period recommended ongoing use of 6 monthly
AFP and abdominal US. A local tumour marker database consisting of all AFP samples col-
lected within the region was interrogated for patients receiving 2 AFP levels within a 24
month period (samples3 months apart) with at least one AFP measurement in 2009.
Dynamic Alpha-Fetoprotein in Hepatocellular Carcinoma Screening
PLOS ONE | DOI:10.1371/journal.pone.0156801 June 16, 2016 3 / 22
Exclusion criteria were age<18 years, suspicion of germ cell tumour, no recorded indication
for HCC surveillance as outlined by international guidelines [9, 10], and previous HCC. After
rigorous data-checks on an initial database, 1,509 patients with 14,842 AFP readings met inclu-
sion criteria, forming the ‘HCC surveillance cohort’ with data through March 2012 in all
instances. For individual cases, the data retrieved and anonymized were: age in 2009, sex, aeti-
ology of liver disease, AFP dates and results. Aetiology was coded as: alcoholic liver disease
(ALD), Hepatitis C virus (HCV), non-alcoholic fatty liver disease (NAFLD), Hepatitis B virus
(HBV), primary biliary cholangitis (PBC), haemochromatosis (Haem), Autoimmune liver dis-
ease (AILD), and other. Additional prospective data on specific trigger-case (see later) and con-
trol sets were retrieved as described subsequently. For calculation of HCC-free survival, follow-
up time was calculated from first AFP measurement date in 2009 to either i) last census date
prior to April 2012 (which comprised the dataset for full analysis) or ii) date of diagnosis of
HCC. Overall, HCC development rate was 1.67 HCC per 100 patient years (75,933 follow up
days for 59 cases where HCC developed and 1,215,639.5 days for 1,509 HCC-free cases allow-
ing for 131.5 days extra per person [half the mean interval between AFPs of 263 days—see
results]). Follow up days were determined by time from first AFP reading after 01/01/2009 and
either HCC diagnosis or last AFP prior to census of AFP database (31/03/2012). Data have
been deposited in Edinburgh DataShare: http://dx.doi.org/10.7488/ds/1397.
Exploratory analysis of the finalized AFP-database
Analyses were stratified by aetiology, and particular interest focussed on a sub-cohort of 1048
patients with at least six AFPs. We assessed linearity of log10-AFP (hereafter log-AFP) against
historical-time, back from the most recent screen, so that patient-intercepts were our best esti-
mate for ‘true’ log-AFP at the patient’s most recent AFP-screen. Linearity was tested for all
available screenings; and for the most recent six.
Per-patient, whether a linear trend adequately described the patient’s time-ordered log-
AFPs was summarised by R2 (the proportion of variation in log-AFPs explained by linearity).
Within each aetiological group, we focused on patients for whom linearity explained at least
30% of the variation in their log-AFPs. However, it also mattered if the estimated gradient was
negative, indicating increasing AFP-levels to the most recent.
Bayesian analysis plan
Initial insights: The Bayesian analysis first contrasted linearity for the four major diagnostic
groups by analysing only those patients for whom there was adequate support for linearity
either on the basis of all, or the six most recent, log-AFPs. This initial analysis, which fitted an
indicator for early-diagnosed HCC cases, confirmed that the log-AFP intercept was highest
and gradient most strongly negative for early-diagnosed HCC cases; with the HCV sub-cohort
next in line.
The initial Bayesian set-up allowed estimation of parameters (such as aetiological-mean
intercepts) when based on all screened log-AFPs or when windowed-in on the most recent six.
Aetiology-specific standard deviations measured how variable patient-specific estimates were
about their aetiological-means—whether in terms of intercept or gradient.
Definitive Bayesian analysis: entry criteria
Individuals were included in this analysis if they met the following criteria: (i) at diagnosis the
HCC was considered 'potentially curable', as defined by current UK liver transplantation crite-
ria [32, 33]; (ii) at least six AFPs were available; (iii) the liver disease aetiology was one of the
four main aetiology groups—ALD, HCV, NAFLD, and HBV; and (iv) at any point in their
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chronology, a patient’s most recent six log-AFPs, or all log-AFPs up to and including the most
recent, provided an R2 greater than 0.3.
Bayesian analysis: static and dynamic modes
Ultimately, we needed to apply our Bayesian analysis dynamically once a patient had achieved
six or more AFPs and sufficient evidence of linearity, as per the entry criteria. Early-diagnosed
HCC cases sit within their aetiology, rather than have a separate indicator. The training data-
set, albeit dynamically-defined, was initially analysed in respect of the maximal AFP trajecto-
ries for those who had met the entry criteria (that is: in static mode) to determine trigger-
regions, defined by patients’ estimated log-AFP intercept and gradient, in which most of the
early-diagnosed HCC cases were located.
The training data-set was then analysed dynamically (from wave 1 to the final wave W,
which coincides with the static analysis, see S1 Supporting Methods) to establish the likely
recall/re-screening burden occasioned by possibly-repeated triggering as a patient’s data accu-
mulated. Additional methodological description of the Bayesian analysis is provided in S1 Sup-
porting Methods. The Bayesian hierarchical linear model, which underlies our dynamic
Bayesian algorithm, was fitted using OpenBUGS software [34].
Case controls analysis
Case-controls analysis was performed using 32 cases which triggered our dynamic Bayesian
analysis. For each trigger-case and trigger-year, five controls matched for i) aetiology, ii) sex,
iii) age to within five years and iv) ongoing AFP screening to within 1 calendar-year of trigger-
case year, were randomly selected by PD and SMB; and outcome information during the 2009–
2014 was gathered by TGB. As trigger-cases could signal in more than one calendar-year, we
present information from controls for the earliest trigger-year only.
By design, the ‘HCC surveillance cohort’ excluded patients who were HCC-diagnosed prior
to 2009. The calendar-year of first-triggering by the listed trigger-cases may have been pre-
2009 but the case-control assessment is based on person-months at-risk from the later of Janu-
ary 2009 or first trigger-year. The count of person-months is terminated by the earliest of three
events: HCC diagnosis, OLT (orthotropic liver transplant) or death, with the month of the
event’s occurrence counted as an at-risk month.
Results
Part 1
Epidemiology of HCC development in a loco-regional Scottish cohort. During the six
years of 2009–2014, 304 new cases of HCC were diagnosed in the Lothian region, 77% of
whom were male. Median age at diagnosis was in the seventh decade, see Table 1. The most fre-
quent aetiologies of cirrhosis were ALD, NAFLD and HCV. Median survival following HCC
diagnosis was 539 days; survival at 1, 2 and 5 years post-diagnosis was 58%, 42% and 21% (Fig
1a). Tumour characteristics at diagnosis are shown in S1 Table.
Clinical events leading to the detection of HCC. Detailed case review established the
clinical events leading to HCC diagnosis. The largest single reason for HCC detection was par-
ticipation in an HCC surveillance programme which accounted for 44% (n = 133) of all
detected HCCs (Table 1). However, 14 (11%) of these had their HCC detected by investigations
outwith routine screening: detection in eight patients was during assessment for liver trans-
plantation for decompensated liver disease, two had hepatological indications for repeat imag-
ing (decompensation and portal vein thrombosis) and four patients received either CT or MRI
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for other indications (altered bowel habit; assessment of Crohn’s disease; weight loss following
acute myocardial infarction; weight loss and altered bowel habit with history of colorectal car-
cinoma). Despite screening, a further four patients had no known HCC until liver explant
examination confirmed tumour; of these, three had maximal tumour size of 1cm (1, 2 and>5
lesions) with the other patient having extensive multifocal disease (maximum diameter
63mm). Of the remaining 115 surveillance-detected HCCs, the majority (n = 90) had
6-monthly imaging and AFP; referred to as optimal screening. Five of this optimally screened
group had regular cross sectional imaging (CT/MRI with contrast) because of insufficient US
views due to body habitus. The other 25 patients had less regular HCC screening investigations,
by reason of failure to attend or unexplained omission of screening by clinicians; termed sub-
optimal screening.
Symptoms consistent with HCC development (weight loss, right upper quadrant pain, itch,
hepatic decompensation, or pain/effusion consistent with sites of metastasis) accounted for
Table 1. Demographics and route to diagnosis in HCC patients.
A
Variable HCC n = 304
Sex/male (%) 235 (77)
Age† 68 (17–98)
Male 68 (17–98)
Female 69 (33–88)
Aetiology/% (*)
Alcohol related liver disease 21.7 (37.5%)
Non alcohol related fatty liver disease 19.7 (26.3%)
Hepatitis C 13.8 (21.7%)
Hereditary haemochromatosis 2.6 (4.6%)
Hepatitis B 3.3 (4.3%)
B
Total HCC n = 304 100%
Index event triggering diagnosis
Screening 133 43.80%
Standard optimal (‡) 90 29.6% (1.6%)
Suboptimal 25 8.20%
Detected incidentally out with screening (††) 14 (8) 4.6% (2.6%)
Detected only on transplant explants 4 1.30%
Symptomatic consistent with HCC 67 22.00%
Presentation (‡‡) 53 (4) 17.40%
Incidental ﬁnding on imaging 47 15.50%
Aetiology is given for the 5 most prevalent. Percentages apply for cases where only a single aetiology was
deﬁned; bracketed percentages refer to the total of cases where aetiological factor was either alone or as a
cofactor. Other aetiologies were %; AIH 2.3 (2.3), PBC 3.0 (3.3), PSC 0 (0), Hepatic sarcoid 0.3 (0.3),
Secondary haemochromatosis 0.3 (0.3), Conﬁrmed non cirrhotic 1 (1), Cryptogenic cirrhosis 15.5. (% total
of sole aetiology and as cofactor).
†Median (range),
*Sole aetiology (total of sole and cofactor),
‡Optimal, but CT/MRI due to habitus,
††incidental at OLT assessment,
‡‡Representation to liver clinic.
doi:10.1371/journal.pone.0156801.t001
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Fig 1. AFP as an HCC surveillance tool detects a significant number of treatable HCC in patients with
satisfactory outcomes. A) Survival for total HCC cohort diagnosed with HCC between 1/1/2009 and 31/12/2014.B)
The role of AFP in HCC detection. Method of HCC detection for the 133 patients within HCC surveillance programme
at the time of diagnosis, chequered area within AFP pickup group represents the 28/49 patients in whom a recent US
had not been performed—see text for details.C) Individual AFP levels at time of diagnosis for patients diagnosed with
Dynamic Alpha-Fetoprotein in Hepatocellular Carcinoma Screening
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22% of all detected HCCs (n = 67). Fifty-three HCCs (17%) were detected by investigation of
patients referred for abnormal LFTs, hepatomegaly, newly diagnosed HCV or for investigation
of symptoms not consistent with underlying HCC. A further four patients (1.3%) had HCC
detected at re-engagement with specialist services having been previously lost to follow up.
Finally, 47 HCCs (16%) were detected incidentally on imaging performed for other reasons
including aortic aneurysm surveillance, assessment of peripheral vascular disease, haematuria,
dyspnoea, and entry into research studies.
The role of AFP surveillance HCC detection in our patients. From clinical records we
ascertained the contribution of AFP to HCC diagnosis for 129 patients undergoing HCC sur-
veillance (excluding the four incidental tumours found at liver transplant explant analysis).
Ultrasound (US) detected an initial lesion in 61 cases (48%), of whom 59 had an AFP level
taken within 6 months of diagnosis (Fig 1b). Twenty-nine (48%) had raised AFP levels (local
upper limit of normal [ULN]6kU/L) at diagnosis (Fig 1c).
Detection of HCC was frequently because clinical interpretation of AFP led to altered man-
agement resulting in HCC diagnosis. This occurred in 49 of the 129 (38%) patients whose
HCC was detected whilst in an active screening programme (Fig 1b) and whose sole indication
for conversion to cross-sectional imaging had been the rising AFP. Twenty-one of the 49 had
an US within 6 months prior to HCC-diagnosis which had failed to identify any suspicious
lesion. Eighteen of the 49 cases (37%) were in optimal HCC surveillance with long-term regular
6-monthly US and AFP. Details of the other 28 cases with AFP-flagged HCC diagnosis in
whom no recent US imaging was performed are given in S2 Table. Median AFP at HCC-diag-
nosis in this group of 49 patients was 77kU/L (Fig 1c and S1 Table).
Outcomes for patients by the modality of HCC detection. Due to the importance of sur-
veillance to detect HCC with a potentially favourable clinical outcome, we analysed the survival
of HCC patients detected by AFP versus US. Median survival for 49 AFP-detected HCC was
729 days post-diagnosis compared to 1043 days in 61 patients with US-detected HCC, but the
difference in survival was not statistically significant (Fig 1d).
The aim of surveillance is to facilitate intervention for early stage HCC. At diagnosis, 78%
and 65% in the US and AFP detected groups respectively met UK liver transplantation criteria
for size and number of HCC lesions (S1 Table). Applying the additional, current UK liver
transplantation criterion, for an upper AFP limit of 1000kU/L, zero and four patients in the US
and AFP detected groups respectively became ineligible. All four cases excluded by an AFP
>1000kU/L had solitary tumours of size 25, 27, 30 and 45mm.
To assess if detection of HCC by AFP was futile with regard to treatment options, specific
treatments actually received for HCC were compared: 44% (27/61, 95% CI: 32%-57%) of
patients with HCC detected by US were offered a potentially curative therapy (either resection,
RFA or liver transplantation) compared to 35% (17/49, 95% CI:22%-48%) of patients with AFP
detection (Fig 1e and S1 Table); 23% and 33% respectively were offered best supportive care;
29% and 35% received transarterial chemo-embolization with doxorubicin/lipiodol (TACE)
monotherapy, often in repeated sessions. In summary, 75% and 65% of the US and AFP
HCC, AFP values plotted at log10; AFP = 6 (local ULN; yellow) and AFP = 20 (red) are shown. All columns p<0.0001
to one another by Kruskal Wallis test with Dunns multiple comparison. D) Survival of patients with HCC diagnosed
through surveillance screening either through US or AFP mediated conversion to CT/MRI imaging, error bars = SEM,
p value denotes Mantel Cox. E) Therapy offered to patients within each group (US detected n = 61 and AFP detected
n = 49) of patients with HCC detected during surveillance; all p>0.05 by 2 way Anova. Of the 11 and 9 patients listed
for liver transplantation, 2 (due to tumour growth) and 1 (due to frailty) were delisted from the waiting list whilst
awaiting transplantation in US and AFP detected groups respectively.
doi:10.1371/journal.pone.0156801.g001
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detected HCCs received surgical/interventional radiological therapy, confirming that detection
of HCC through the use of AFP does not result in futile detection of untreatable HCC.
Patient outcomes by AFP at HCC diagnosis. Elevated AFP has been associated with
poorer outcome following HCC diagnosis, particularly around the level of>20kU/L, often
used as a decision limit [35–37]. We therefore examined the effect of AFP at diagnosis on
patient survival. In the whole HCC cohort, a cut-off of AFP>20kU/L separated cases with dif-
fering survival (Fig 1f). This separation was preserved when applied to the cases detected by
either US or AFP within a screening cohort. Nine of the 49 cases (18%) detected solely by AFP
fell below this cut-off. Therefore, in this study, an individual patient’s outcome was dependent
on the AFP value at diagnosis and, if AFP is to be used in HCC surveillance, early recognition
of a rising AFP may be crucial to prevent the patient entering a poorer prognostic group.
Serial AFP look-back in the ‘HCC case series’. Detailed review of the clinical records of
patients whose HCC detection was prompted by a rising AFP revealed that, in most cases, ele-
vation above a baseline for that patient prompted a conversion (often temporary) to CT/MRI
based imaging over US. Locally, clinicians were provided with a graphical representation of
AFP values over time with each AFP result. We hypothesised that such use of graphically pre-
sented serial AFPs aided clinicians’ interpretation of the relevance of an individual’s recent ver-
sus past AFPs and that a combination of current value and rate of increase were key features in
their decision making process.
Examining all patients with ‘AFP detected’HCC reveals an apparent inflection of AFPs
prior to their diagnosis, consistent with our hypothesis (Fig 2a). Examining individual cases
more closely, this effect becomes more apparent (Fig 2b). None the less the decisions to alter
patient management based upon AFP variations were not standardised, sometimes inconsis-
tent and difficult to put into agreed protocol due to the complexity of recognising what was
considered ‘at risk’ versus ‘not at risk’. We therefore set out to assess more rigorously the case
Fig 2. Dynamic AFP changes associated with HCC development. A) Plotting each individual’s time course of serum AFP relative to diagnosis an
elevation in values is observed prior to diagnosis. Here all individuals in the HCC review in whom AFP influenced clinical management (n = 49) are
charted with AFP on a log10 scale.B) Graphic demonstrates the concept of gradient and intercept over a specific individual’s time course.C) The
screening cohort of 1509 patients followed over time for development of HCC, overall incidence at end of index screening (1186 days from 01/01/2009,
total HCC free % = 93.7).
doi:10.1371/journal.pone.0156801.g002
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for monitoring how serial AFPs evolve and describe the analysis of serial AFPs in untutored
observer fashion, in order to establish a standard for interpretation of dynamic AFP results.
Part 2
The ‘HCC surveillance cohort’. To investigate further the role of AFP in HCC detection
within our region, we identified patients undergoing HCC surveillance in 2009; termed ‘HCC
surveillance cohort’. The year, 2009, was chosen so that all patients developing HCC could be
cross-referenced to our HCC cases. In total, 1509 patients were identified by predetermined
criteria—see Patients and Methods section. Eighty seven of these patients developed HCC by
January 2015, 59 by the analysis-date of 31 March 2012 which corresponds to an average HCC
development rate of 1.67 per 100 patient years (Fig 2c).
Exploratory analysis of the ‘HCC surveillance cohort’ and ‘HCC case series’. Having
two separate data sets (one comprising all HCCs diagnosed within the region, the other a pro-
spective cohort of HCC-free patients in HCC screening) combined with all AFP results and
dates in both sets, the work flow Fig 3a shows how, after rigorous data-checks, we utilized the
available serial AFP values for 1509 validated patients in the HCC surveillance cohort to devise
a standardised algorithm for detecting high risk AFP values for an individual. We elected to
use a Bayesian approach which allows interpretation of an individual’s AFP history to draw
strength from the history of others from the same aetiology. This method attaches a posterior
probability to the intercept and the gradient of a log-AFP history lying within a trigger region
to identify high HCC risk.
The two most common aetiologies in Lothian’s HCC surveillance cohort of 1509 patients
were ALD (426 patients) and HCV (406 patients). The cohort was predominantly male (57%)
but, for two aetiologies in particular, PBC (101 patients) and AILD (80 patients), females pre-
dominated: 88% and 80% respectively (Table 2). Mean age in 2009 was 55 years but was higher
in ALD patients (58.8 years, se 0.5 years) than for HCV patients (48.2 years, se 0.5 years).
Mean of log-AFP at the patient’s most recent screen was similar at 1.35 (se 0.026; back
transformed 5th and 95th centiles for AFP 2.9 to 173) for ALD patients and 1.42 (se 0.039; back
transformed 5th and 95th centiles for AFP 1.3 to 524) for HCV patients. However the standard
deviation (sd) for log-AFP at both first and most recent screen was much higher for HCV
patients (around 0.80) than for ALD patients (around 0.55); and, for ALD patients but not for
HCV patients, mean log-AFP had decreased from first to most recent screen.
Table 2 also presents equivalent data values for the 1048 patients which at least six AFPs
and the 672 patients in the four main aetiologies whose AFP trajectory gave sufficient evidence
of linearity to admit them to the definitive Bayesian analysis (see below).
Prior to definitive Bayesian analysis, three checks were necessary, these and their results are
summarised in S3 Table. With the data having passed all three of our preliminary checks we
proceeded to the definitive Bayesian analysis.
Bayesian analysis (in waves) of the ‘HCC surveillance cohort’ and ‘HCC case series’.
We let pi denote the "point of entry" (into our dynamic analysis) for individual i. Traversing
his/her data chronologically, “point of entry” is defined as the observation number at which
his/her log-AFPs first provided an R2 greater than 0.3 for linearity, either over the most recent
six AFPs or for all AFPs up to and including the most recent.
Our dynamic analysis comprised 48 waves, indexed by w. For wave 1, our data-set com-
prises all AFPs up to (and including) the point of entry for each individual. We then consider
that all individuals are `synchronised' at this point with subsequent AFP measurements also
arriving in synchronised fashion. The data-set grows in each subsequent wave such that a single
additional AFP reading is included for each individual, if available (Fig 3d).
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Fig 3. Using dynamic analysis of AFP provides a methodology for identifying patients at high risk of HCC. A) Workflow for the development of an
algorithm for HCC detection using AFP. The HCC surveillance cohort refined to patients with specific characteristics prior to formal Bayesian analysis in
static and dynamic modes. In static mode a trigger zone was established, which was then tested dynamically. Estimated patient-specific intercept and
gradient parameters plotted against each other. Estimates were taken from `windowed' versionB) `full-data' versionC) of full-trajectory retrospective
Bayesian analysis. Triangles denote confirmed early-diagnosed HCC cases. Diagonal lines define regions of parameter space (above the line) that might
indicate emerging HCC cases: purple—passes through (x, y) = (-0.01, 1) and (0, log20); brown—passes through (x, y) = (-0.01, 0.5) and (0, 1); yellow—
Dynamic Alpha-Fetoprotein in Hepatocellular Carcinoma Screening
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In static mode, our Bayesian algorithm analyses only the final (wave 48) data-set. But,
dynamically, the analysis runs at each wave of data-acquisition (1 to 48). For each aetiology
(denoted by k), the algorithm allows intercepts and gradients to differ randomly across
patients.
yij ¼
X4
k¼1
ak
i
xik þ
X4
k¼1
b
k
i
xikðzij=100Þ þ eij
aki  Nðmak; s
2
akÞ; b
k
i  Nðmbk; s
2
bkÞ; eij  Nð0; s
2
i Þ
In the equation above, yij denotes log-AFP for patient i at measurement time j, the covariate
zij represents number of days since last screening and the indicator xik takes the value 1 if
patient i has aetiology k, zero otherwise. The model is explained in more detail in the S1 Sup-
porting Methods section.
In static mode, the algorithm allowed us to specify trigger regions which appeared to iden-
tify patients at high risk of HCC development. We tested the chosen trigger region (coloured
yellow, Fig 3b and 3c) and 0.67 posterior probability threshold by analysing the HCC surveil-
lance cohort data dynamically. This identified 32 cases who triggered (often repeatedly) high
risk AFP behaviour. Individual graphs for these cases are presented in S1 Fig.
Table 3 shows the algorithm’s parameter estimation at wave 1 and wave 48, each analysis
pertaining to 672 patients from HCC surveillance cohort and their 22 early-diagnosed HCC
counterparts. Median intercept is highest (0.68 at wave 48) and the gradient most negative for
the HCV patients. Comparison between waves 1 and 48 shows, for the windowed analysis espe-
cially, the extent of learning about median gradient which for HCV patients was from -0.001 at
wave 1 to -0.003 by wave 48.
Case control analysis. To test prospectively the algorithm developed above, we designed a
case control study using the 32 cases who triggered in our dynamic Bayesian analysis, 29 of
whom were HCV patients. For each trigger-case and trigger-year, we selected five matched
controls from the ‘HCC surveillance cohort’–see Patients and Methods section for matching
details. One control had HCC diagnosed in December 2008 (and therefore should have been
excluded, but was not due to lack of clinical information prior to the detailed look-back). We
have retained this control as an HCC-case, using OLT-date in 2009 as the event-month.
In 10 HCV case-control sets, HCC developed in 11 patients (Table 4); 6 of the 29 cases
which triggered the algorithm developed HCC. In five sets, the trigger-case but none of the five
controls developed HCC. The probability of this most-extreme out-turn is [1/6]5 or 1.286 
10−4. In four sets, one of the five controls was subsequently diagnosed with HCC but not the
trigger-case. The probability of this, or a more extreme, out-turn is [5/6]4 + [1/6]4 or 0.483. In
the final set, there were two HCC diagnoses, the HCV trigger-case and one of five controls.
The probability of this, the most extreme out-turn for two HCC diagnoses, is 5/15 or 0.333. In
summary, had the chance of HCC diagnosis during 2009–2014 been identical for HCV trigger-
cases and controls, the probability of outcomes as extreme as we have observed when multiply-
ing across our 10 informative case-control sets, is extremely low: 2.07  10−5.
passes through (x, y) = (-0.01, 0.5) and (0, log20). The area to the above/left of the yellow line was used to represent the area of ‘high risk’ characteristics
of AFP. D) Illustration of triggering across waves of prospective Bayesian analysis. All HCC patients from the HCV group are shown, along with an equal
number of non-HCC cases from the same group. A point is plotted for each trigger (HCCs denoted by triangles and non-HCCs by circles); a horizontal line
is shown for patients who did not trigger at all. Points of a lighter shade are used to indicate that the patient-specific data are the same as in the preceding
wave due to that patient's data set having ceased to accrue more AFPs in the training data-set.
doi:10.1371/journal.pone.0156801.g003
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Finally, our 29 HCV trigger-cases experienced six HCC diagnoses in 1,689 person-months
at-risk during 2009–2014, an HCV trigger-case diagnosis-rate of 4.3 HCCs diagnosed per 100
person-years at-risk (95% CI: 1.56 to 9.28). For the 145 HCV controls, there were five HCC
diagnoses in 9,218 person-months at-risk during 2009–2014, an HCV controls’ diagnosis-rate
of 0.65 HCCs per 100 person-years at-risk (95% CI: 0.21 to 1.52), which is significantly lower
as clearly indicated by non-overlapping Poisson-based 95% confidence intervals.
Retrospective review of the case histories of the six HCV cases who triggered an ‘at risk
alert’ by the algorithm and went on to develop HCC (Table 4) revealed that, in two of the six
cases a HCC was detected by a lesion on US leading to diagnosis on initial cross sectional imag-
ing within 3 months. Another one of the six cases had a prior lesion on US which was subse-
quently followed up by cross sectional imaging leading to HCC diagnosis 13 months
subsequently. Hence, in half of these six cases AFP did not significantly affect HCC detection.
In only one case did the rising AFP lead to a direct change of patient surveillance management.
Here, a clinician detected the rising AFP (without the help of the algorithm) and converted sur-
veillance to regular cross sectional imaging with ongoing AFP monitoring. The AFP then con-
tinued to rise and HCC was diagnosed 36 months later (AFP—355 at diagnosis) and treated
with local regional therapy. The patient was still alive at census. In the last two cases in which
Table 3. Model coefficients obtained from full-data and windowed analyses in static mode (wave 48) and dynamic mode (wave 1).
Parameters in the Bayesian
algorithm
Intercept for the
aetiological population
(most recent log10-AFP)
Intercept for the
individual (sd. of
individuals about their
aetiological mean)
Gradient for the
aetiological population
Gradient for the
individual (sd. of
individuals about their
aetiological mean)
μα σα μβ σβ
Median 2.50% 97.50% Median 2.50% 97.50% Median 2.50% 97.50% Median 2.50% 97.50%
Full-data analysis, Wave48
ALD 0.58 0.55 0.6 0.19 0.17 0.21 0.004 0.003 0.005 0.008 0.007 0.009
HCV 0.68 0.64 0.72 0.37 0.34 0.40 -0.001 -0.003 0.0003 0.011 0.010 0.013
NFALD 0.57 0.52 0.63 0.21 0.18 0.26 0.006 0.003 0.008 0.008 0.005 0.011
HBV 0.45 0.41 0.49 0.17 0.15 0.21 0.001 -0.001 0.002 0.006 0.004 0.007
Windowed analysis, Wave48
ALD 0.57 0.54 0.59 0.18 0.17 0.20 0.003 0.001 0.005 0.010 0.007 0.012
HCV 0.68 0.64 0.72 0.35 0.31 0.38 -0.003 -0.005 -0.001 0.010 0.008 0.013
NFALD 0.59 0.54 0.64 0.2 0.17 0.25 0.0002 -0.004 0.004 0.012 0.008 0.018
HBV† 0.44 0.4 0.48 0.18 0.16 0.21 0.0001 -0.001 0.001 - - -
Full-data analysis, Wave1
ALD 0.61 0.58 0.64 0.18 0.16 0.20 0.001 0.0001 0.003 0.005 0.003 0.006
HCV 0.66 0.62 0.7 0.28 0.25 0.32 -0.001 -0.002 0.001 0.008 0.007 0.009
NFALD 0.56 0.49 0.62 0.23 0.19 0.29 0.007 0.004 0.011 0.010 0.007 0.014
HBV 0.48 0.43 0.54 0.2 0.16 0.24 -0.0003 -0.002 0.002 0.006 0.004 0.008
Windowed analysis, Wave1
ALD 0.60 0.57 0.63 0.19 0.17 0.22 0.003 0.001 0.004 0.010 0.008 0.012
HCV 0.67 0.63 0.72 0.30 0.27 0.35 -0.001 -0.003 0.001 0.011 0.009 0.013
NFALD 0.54 0.47 0.61 0.25 0.20 0.31 0.010 0.005 0.014 0.015 0.012 0.020
HBV† 0.44 0.38 0.51 0.20 0.17 0.25 0.001 -0.002 0.004 - - -
Posterior medians and 2.5%, 97.5% values are shown.
†The data did not support between-patient variability of the windowed parameters for HBV patients.
doi:10.1371/journal.pone.0156801.t003
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Table 4. Case-controls study assessing the performance of our dynamic Bayesian algorithm for identifying HCV cases at higher risk of HCC-diag-
nosis during 2009–2014.
Case ID Diagnosis, Gender, Age
@2009
1st trigger
year
Death
Month/yr
HCC Month/
yr
OLT Month/
yr
TACE
Month/yr
RFA Month/
yr
Person-
months
11 HCV, m, 56 2007 Jul-13 Jun-11 Sep-11 30
5controls Jun-11a * * 7+246 = 253
†Dec-08b †Jul-09b
39 HCV, m, 56 2006 * Jun-11 * * * 30
5controls 360
241 HCV, f, 69 2010 Dec-14 60
5controls Mar-12 267
326 HCV, f, 66 2002 * * * * * 72
5controls Mar-12a Dec-14b 327
474 HCV, m, 62 2008 * * * * * 72
5controls Jan-10 301
487 HCV, f, 62 2006 Mar-14a Jul-14a Jul-14a 63
5controls Mar-12 327
617 HCV, m, 59 2007 * * * * * 72
5controls Oct-09 298
632 HCV, m, 58 2011 * * * * * 48
5controls Apr-14a Apr-13a 220
646 HCV, m, 58 2008 * * * * * 72
5controls Oct-09a 279
13b May-13b
754 HCV, m, 56 2010 Apr-14a Apr-13a 40
5controls 300
809 HCV, m, 55 2007 Apr-10 16
5controls 360
812 HCV, f, 55 2003 * * * * * 72
5controls 360
818 HCV, f, 55 2009 * * * * * 72
5controls Jul-12a Aug-10b 308
827 HCV, m, 55 2005 * * * * * 72
5controls Jun-13a Feb-14a Dec-13a 342
840 HCV, m, 54 2010 Apr-14a Jun-14a 52
5controls 300
848 HCV, f, 54 2009 * * * * * 72
5controls 360
859 HCV, m, 54 2009 * * * * * 72
5controls 360
926 HCV, m, 53 2006 * * * * * 72
5controls 360
936 HCV, m, 52 2002 Jun-11 30
5controls 360
938 HCV, m, 52 2006 * * * * * 72
5controls Dec-13 348
943 HCV, f, 52 2009 * * * * * 72
5controls Jan-14 349
1008 HCV, m, 51 2009 * * * * * 72
(Continued)
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the algorithm detected ‘high risk’HCC behaviour during screening prior to HCC development,
the AFP did not change clinical management and the HCC was detected incidentally by cross
sectional imaging performed for decompensated liver disease (jaundice and ascites). In both
cases an US was performed within 6 months of HCC diagnosis and detected no clinically sig-
nificant lesion. Of these two patients, one was dead within a year and received no specific
Table 4. (Continued)
Case ID Diagnosis, Gender, Age
@2009
1st trigger
year
Death
Month/yr
HCC Month/
yr
OLT Month/
yr
TACE
Month/yr
RFA Month/
yr
Person-
months
5controls Apr-11 316
1156 HCV, m, 47 2009 * * * * * 72
5controls Dec-13a Apr-13a 340
1164 HCV, f, 46 2004 Sep-11 33
5controls Feb-11 314
1223 HCV, m, 45 2009 Oct-14 70
5controls Feb-12 326
1233 HCV, m, 44 2006 * * * * * 72
5controls 360
1359 HCV, m, 40 2007 May-10 17
5controls Apr-13a 338
Oct-14b
1378 HCV, f, 39 2010 * * * * * 60
5controls May-11a 247
Feb-14b
1403 HCV, m, 37 2010 Dec-13 60
5controls Dec-09a 12+226 = 238
Oct-13b
cases 29 7 6 2 2 1 1689
controls 145 21 5 5 1 0 9218
Non HCV cases
39 NFALD,m,79 2005 2012
2controls 2010a
2013b
890 ALD, f, 53 2011 2011 Not analysed
4controls 2014
1148 ALD, m, 47 2011 Jun-13
5controls 2011a Jul-10d
2012b
2013c
Individual cases triggering the deﬁned algorithm are presented by their identiﬁer (ID) within the AFP surveillance cohort together with basic demographic
data used to match 5 controls. Columns highlight cases of death, HCC diagnosis, OLT, and either TACE or RFA non-surgical management. Person-
months denotes the follow-up period. One control for case 818 had HCC based upon a single CT, but no HCC was detected upon repeat imaging (with
MRI and CT) prior to OLT without speciﬁc anti-HCC therapy, nor at transplant explant examination seven months later. This case was therefore not listed
as HCC in the database nor considered as bona ﬁde HCC in the case-control assessment.
† Denotes a patient who, upon review, was diagnosed with HCC prior to the point of patient inclusion of 1/1/2009 but is analysed by OLT-date.
*denotes absence of events.
Superscript letters are used to differentiate separate individuals in the control groups.
doi:10.1371/journal.pone.0156801.t004
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HCC-therapy; the other received a liver transplant 4 months after diagnosis and following
loco-regional HCC therapy and was alive at census.
Discussion
The objective of this study was to assess in patients within an HCC surveillance programme
the potential of serial AFP analysis to improve detection of treatable HCC specifically where
US shows no lesion. Here we report the local experience of using AFP over a five year period in
a well-defined and followed up loco-regional series of patients undergoing AFP surveillance
and/or management of HCC. In our hands, the use of serum AFP in HCC surveillance has
facilitated the early diagnosis of HCC in a large proportion of the patients undergoing HCC
surveillance in whom the HCC was otherwise not detected by US alone. Despite this group’s
elevated AFP levels at HCC diagnosis, potentially curative therapy was offered in the majority
of instances, including offers of surgical therapy (resection and or liver transplant). Impor-
tantly, the AFP-detected HCC cases were not disadvantaged in terms of survival. We therefore
believe our data provide good evidence for the use of AFP in HCC surveillance programmes.
We therefore set out to develop mathematical model to aid healthcare workers in discrimi-
nating between benign variability in AFP, and variations which may reflect the development of
an underlying HCC. Such a model should provide a standardised accurate and validated inter-
pretation of AFP results and ideally have the potential to be optimised iteratively when further
data is available.
In this proof of principle study we show that an automated algorithm for monitoring
dynamic changes in AFP is able to identify patients at high risk for HCC development. The
cases analysed in this study had principally HCV related liver disease. This algorithm has the
advantage that it may be further refined by the inclusion of larger data sets, including those in
which other aetiologies predominate. The dynamic Bayesian approach has the potential to
offer an automated and validated interpretation of an individual’s screening AFP results in the
context of other in the same aetiological group. It takes into account the individual’s AFP his-
tory as well as his/her most recent six AFPs and other information: specifically, aetiology of
liver disease. Automating such an analysis and adding a user friendly interface would provide
immediate data interpretation following biochemical analysis and unambiguous interpretation
of results by specialists and non-specialists alike. Lack of consensus on how to interpret results
from AFP screening is a significant barrier to performing optimal HCC surveillance even in
westernised healthcare systems and such a system could therefore provide a much needed
improvement.
Currently this study has been restricted to a subset of the total cohort of patients undergoing
HCC surveillance. A clear limitation to this proof of concept study is that is has not been vali-
dated, to date, in an independent external cohort. Currently we have examined the utility of
this approach for four main aetiologies and only for screened patients with at least six AFP
measurements and evidence of linearity: 672 out of a total of 1148 patients (59%) whose aetiol-
ogy was ALD, HCV, NAFLD or HBV. However this corresponds to 83% of the 814 with at
least six AFP measurements, our minimum threshold for establishing patient-specific log-AFP
trajectories. In total, by addition of 22 Lothian patients with these aetiologies whose HCC was
diagnosed early and had at least six AFPs, 694 patients were included in the derivation of this
algorithm and we would plan to extend this in future work.
The restriction to early-diagnosed HCC cases was quite limiting in terms of the number of
patients whose log-AFP screening profile could be learned from and so future work will: i)
increase the pool of early-diagnosed HCC cases by which to ‘train’ the Bayesian analysis in
Lothian; ii) validate the Lothian algorithm for external cohorts; iii) try reducing the
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entry-threshold from six AFPs, as Bayesian learning between wave 1 and 48 was modest; and
iv) test performance of the algorithm when a training set admits HCC cases from the four
main aetiologies whose diagnosis was not made early enough for management with curative
intent to have been offered. We include this fourth proposition because, although we had
hoped that trigger-cases would be imminently an early-HCC-diagnosis, what we have shown is
that the algorithm identifies trigger-cases who demonstrated significantly higher risk of HCC
diagnosis during 2009–2014. This being so, cases in whom HCC was diagnosed late might have
triggered the Bayesian algorithm earlier. Fifth, in line with previous calls to do so [22], our
Bayesian algorithm could be adapted to include other markers such as ALT and other covari-
ates than aetiology, such as sex or ethnicity which has been shown to influence AFP values [13,
18, 19]. Given previous reports of improved AFP levels in patients achieving sustained virologi-
cal response (SVR) to anti-Hepatitis C therapy [38], SVR could also be introduced to patient-
specific algorithms in the future.
Validation on an external cohort is particularly relevant when considering the potential
impact of other factors such as ethnicity or SVR and because variation in aetiological incidence
may account for the relatively low HCC incidence in our cohort (below 2% per year). Further
work is also required for the cohort of patients whose log-AFPs do not conform to linearity.
It is clear that AFP will not provide a faultless screening mechanism independent of, or
combined with, US based imaging. Consistent with previous reports [39], many patients in our
cohort remain with low AFP levels even following extensive HCC development. The secretion
of AFP may in itself identify a separate molecular signature [40]. Alternatively, extreme eleva-
tions of AFP appear to be present in a group in which HCC surveillance is futile due to poor
outcome [33]. A frequent finding in Lothian was that a rising AFP will trigger CT/MRI which
detects an indeterminate lesion, not fulfilling HCC diagnostic criteria. Ongoing follow-up in
such cases remains a dilemma. Consistent with previous reports [41], such indeterminate
lesions in our study often develop HCC defining criteria over a further follow up period. In our
study, we recognised a subgroup of such patients in whom further elevations of AFP were able
to provoke earlier reimaging leading to earlier diagnosis.
As reflection of real world practice, it is noteworthy how many patients undergoing screen-
ing had their HCC detected by other means including clinical trials and imaging performed for
other indications outwith the surveillance programme (see Fig 1c). Similarly despite an inten-
tion to maintain 6-monthly surveillance testing patients did not always have these tests
arranged or performed. This variability in recall and attendance is another feature which often
fails in surveillance programmes and is a further target for improving surveillance programmes
[42].
Numerous related studies have similarly reported on the interpretation of dynamic AFP
changes for specific patients. These studies have similarly focused upon chronic viral hepatitis
[15, 17, 23–25, 27, 43] and have typically used variable cut off values for AFP and/or rates of
AFP elevation—either as multiples of a baseline or over a set time interval both of which pro-
duce potential difficulties when interpreting data over variable and often unpredictable time
intervals. Our well characterized cohort is comparable in size to the largest of these previous
studies [24], the dynamic Bayesian algorithm learns from other patients within the same aetiol-
ogy, and is potentially more flexible to future refinement than those described previously, and
is not constrained by fixed time intervals. Furthermore our approach offers the advantage of
analysis of AFP data samples collected retrospectively, but analysed as if they were occurring in
real time. The advantage of our approach in creating an automated interpretation is that risk
stratification can be automated and delivered direct to the clinician. The current methodology,
which tested both the rate of AFP elevation and its absolute value relative to that individual’s
history, provides an important proof of principle for the application of Bayesian analysis in the
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development of a sophisticated analytical tool to provide much needed addition to ultrasound
in the surveillance of HCC.
Should subsequent validation in larger independent cohorts also support the utility of an
algorithmic approach to AFP monitoring in HCC, we would propose that clinicians should
convert US based surveillance to cross sectional imaging based surveillance in patients identi-
fied as high risk by the algorithm for a time dependent on ongoing AFP activity and the pres-
ence or absence of any indeterminate lesions seen on imaging.
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